List view / Grid view




Kymab secures $100 million Series C funding

1 December 2016 | By Niamh Louise Marriott, Digital Editor

The funds will enable Kymab to advance its proprietary pipeline of first-in-class therapeutic human monoclonal antibodies, with clinical development in 2017...


Kymab and the Wellcome Trust initiate Ebola Project

16 December 2014 | By Kymab

Kymab, a monoclonal antibody biopharmaceutical company, founded on research from the Wellcome Trust Sanger Institute announces that it has been awarded a grant from the Wellcome Trust to lead a consortium developing new treatments in the fight against Ebola...